McCann Health, a part of Interpublic Group (IPG), Monday announced the acquisition of Double Helix, a provider of market research and services to the pharmaceutical and medical device industries. The financial terms of the deal were not disclosed.
Wayne Phillips, who founded Double Helix in 1995, will continue as its CEO and will report to John Cahill, CEO of McCann Health.
McCann Health said Double Helix rounds out its impressive suite of services. The company said Double Helix's focus on innovation and novel collaborations within its network makes McCann Health the most differentiated and endowed, full-service global healthcare communications company.
Double Helix's Market Research division specialises in primary market research for its healthcare clients. The division focuses on the strategic and tactical business needs clients face throughout a product's lifecycle, from pre-clinical to post-launch. Double Helix's Market Access Consulting division assists clients to optimise the life cycle position of products in markets.
With four offices in London, New York, Philadelphia, and Singapore, Double Helix, apart from specialising in the established markets of the US and Europe, also focuses on emerging markets. In the past year, Double Helix has performed projects across more than 40 countries for over 30 major pharmaceutical multinational clients.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org